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2Abstract
The aim of PGD is to test the preimplantation embryo for specific conditions
for couples at risk of transmitting that genetic abnormality to their offspring.
The couple need to go through IVF procedures to generate embryos in vitro.
The embryos can be biopsied at either the zygote, cleavage or blastocyst
stage. PGS uses the same technology to screen for chromosome
abnormalities in embryos from patients going through IVF procedures as a
method of embryo selection. Chromosome analysis was originally performed
using fluorescent in situ hybridisation (FISH) which has now been replaced
by array comparative genomic hybridisation or next generation sequencing
(NGS) For the diagnosis of single gene defects, the polymerase chain
reaction (PCR) has been used and has become highly developed over the
years. More recently, SNP arrays and karyomapping have been introduced.
PGD/PGS require partnership between IVF laboratories and diagnostic
centres. As diagnosis can be performed using a variety of strategies with
different technologies, accreditation of PGD diagnostic laboratories is
important. Accreditation gives IVF centres an assurance that the diagnostic
tests conform to specified standards. ISO 15189 is an international
laboratory standard specific for medical laboratories. A requirement for
accreditation is to participate in external quality assessment schemes
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3The current status of PGD and PGS
Initial clinical application of PGD
PGD was first performed in 1989 and since this time, genetic testing has seen
major advances. PGD was developed as an alternative to prenatal diagnosis,
for couples at risk of transmitting a genetic abnormality to their children.
Couples have to go through IVF procedures to generate embryos in vitro,
even though many of the couples that go through PGD are fertile. The
embryos can be biopsied by the embryologists at the zygote stage (removal of
the first and second polar body), cleavage stage (removal of 1-2 blastomeres
from the 6-8 cell embryo) and blastocyst stage (removal of some
trophectoderm cells)(Harton et al., 2011a). Up until recently, almost all PGD
cycles were performed on blastomeres after cleavage stage biopsy (Harper et
al, 2012, Moutou et al, 2014), but numerous studies have found that cleavage
stage embryos exhibit high levels of chromosomal mosaicism, which means
that biopsied cells may not be representative of the rest of the embryo (Harper
et al, 1995, Munne et al, 1995, Fragouli et al, 2011, Taylor et al, 2014a). This
is especially important when trying to perform PGD for a chromosome
abnormality. Polar body biopsy is rarely used as it only gives genetic
information on the maternal genome. In recent years, the IVF community
have seen an increase in the use of blastocyst transfer (Glujovsky et al, 2012)
and this has been reflected in the increased use of blastocyst biopsy for PGD
(Moutou et al, 2014).
The genetic testing should be performed by a specialised genetic testing
laboratory. The very first cases of PGD were performed using PCR to detect a
4Y chromosome sequence for sexing for X-linked disease (Handyside et al,
1990).
Testing by FISH
FISH replaced PCR as the method of choice for embryo sexing (Griffin et al,
1994, Munne et al, 1995) and for chromosome analysis for patients carrying a
Robertsonian or reciprocal translocation (Conn et al 1998, Fridstrom et al,
2001, Mackie Ogilvie and Scriven, 2002). FISH was limited as specific probe
combinations needed to be used for a particular translocation and so individual
tests had to be validated for each couple. Also FISH is not a very efficient
technique to use at the single cell level (Ruangvutilert et al, 2000). At this time,
some groups decided that PGD technology using FISH to analyse as many
chromosomes as possible might be useful as an embryo selection method for
patients of advanced maternal age, repeated implantation failure or repeated
miscarriage (when the chromosomes in the parents were normal) (Munné et al,
1995, Verlinsky et al. 1995). This technique is usually referred to as
preimplantation genetic screening (PGS) and should be differentiated from
PGD as it is for a different group of patients and for a different reason.
Testing by PCR
PGD for couples at risk of a single gene disorder is usually performed using
PCR (Harper and SenGupta, 2011). This technique has become highly
sophisticated over the years, with one of the most important developments
being multiplex PCR which allows the analysis of the mutation and also a
contamination check (Harton et al, 2011b). Contamination can occur due to a
number of reasons, such as cumulus cell contamination or from people
5handling the cells. (SenGupta and Delhanty 2012). Molecular based analysis
for PGD can either be performed by direct PCR amplification of the biopsied
embryonic sample or following whole genome amplification (WGA). For direct
PCR analysis inclusion of two informative short tandem repeat (STR) linked
markers (within 1cM / 1MB) flanking each side of the mutation site, minimises
the risk of misdiagnosis due to allele dropout at any one locus or due to
contamination. Flanking markers allow the detection of cross over events in
the region and assessment of the reliability of linkage analysis in these
circumstances. The haplotype of the STR markers in phase with the mutation
can be determined by identification of the shared haplotype between family
members of known disease status. The limitation of direct PCR analysis is
that an individual test has to be developed for each couple, which is time
consuming and expensive. Each test has to be validated before being applied
clinically.
The mutation site can be included for amplification in the multiplex reaction.
Minisequencing is a commonly used method for mutation detection
(Fiorentino et al, 2006). For de novo mutations in the male partners the
haplotype in phase with the germline mutation can be determined by the
analysis of single sperm. Similarly for de novo mutations in female partner’s
polar bodies can be used but these must be biopsied sequentially.
Alternatively, phasing of alleles can be carried out from the analysis of
embryos during the PGD treatment cycle however problems can arise when
there are only a few embryos available for analysis. If all the embryos do not
show the mutation and have the same haplotype, it is difficult to be certain
6that the mutation was not present or if allele drop out had occurred at the
mutation site in all the embryos. In such cases rebiopsy may be an option or
cryopreservation of embryos that are blastocysts with analysis of whole
embryos that arrest to confirm the STR phasing with mutational analysis.
Whole genome approaches
The introduction of whole genome amplification (WGA) methods have
enabled the utilization of new, high throughput technologies which have
increased the amount and type of information that can be obtained from an
embryo biopsy sample (reviewed by Hughes et al., 2005). Coupled with this is
a reduction in work up time and the need of patient specific protocols.
Techniques using WGA products are being applied clinically such as
preimplantation haplotyping (PGH) which allows genotyping of multiple STR
markers by PCR, or karyomapping, (SNP genotyping using an array) to
perform PGD by linkage analysis (Renwick et al 2010, Handyside et al.,
2012, Thornhill et al., 2015). The haplotypes obtained using these methods
can also identify monsomies and trisomies of meiotic origin and can
potentially be used to identify imbalances in embryos from translocation
carriers and also distinguish between normal and balanced chromosome
complements. Array comparative genome hybridisation identifies
chromosomal imbalance in a WGA product and has been used in both PGD
for chromosomal rearrangements and for PGS. Next generation sequencing
(NGS) has also been applied for PGS (Wells et al 2014, Tan et al, 2014). It is
expected that NGS will become the method that is primarily used for the
detection of chromosomal imbalance and mutation analysis either as separate
7tests or combined together in one analysis (Tan et al, 2014, Treff et al, 2013).
Currently these whole genome approaches rely on whole genome
amplification. The type of amplification used determines the artefacts that may
be introduced into the sample and thereby affect the accuracy of the
diagnostic test. Thus extensive validation of WGA in the context of the method
of analysis (PGH, aCGH, karyomapping or NGS) with the indication for testing
(chromosomal abnormality, single gene disorder) is required (Bergen et al
2005, Glentis et al 2009).
All direct multiplex PCR protocols require optimisation such that the efficiency
of amplification at each locus approaches 95% and allele drop out is less than
5%. Optimisation needs to be carried out using isolated single cells from each
partner whereby false positive and false negative rates for the overall protocol
can be determined. When whole genome amplification is applied prior to PCR
then optimisation at a single level is no longer necessary. The WGA however
introduces artefacts into the sample and therefore more informative markers
are required to ensure that the protocol is robust enough to overcome any
resulting bias in the sample.
Causes of misdiagnosis in PGD and PGS
It is key that PGD is performed using tests that have been validated and
optimised for the couple, as several reports of misdiagnosis have been
reported (Wilton et al., 2009, Amagwula et al., 2012). The causes of
misdiagnosis include contamination, allele dropout, mosaicism of the embryo,
transfer of the wrong embryo and confusion of the embryo and test numbers.
8Because of these risks, it is essential for the PGD laboratory to be adequately
insured against the risk of misdiagnosis. Patients should be informed of the
limitations of PGD when taking their consent to treatment and witnessing of
appropriate stages during the procedure should be carried out and
documented.
Developments in ART
Besides the need for individual tests for the majority of PGD cycles performed
to date, the diagnosis is constrained as there is a time limit for the results of
the diagnosis. The latest stage that embryos are normally transferred in IVF
is day 6, as current culture conditions cannot sustain embryos for longer and
embryos would normally be implanting around this stage, so they need to be
returned to the uterus. Cleavage stage biopsy allows 2-3 days for the
diagnosis, but blastocyst biopsy gives just 24 hours. This means that PGD
labs have to run a 7 day a week service as the diagnosis has be performed
within 24 hours. Also, running a single test for an array or NGS is expensive,
therefore batching samples for these high throughput technologies makes it
cost effective.
For many years, the freezing technique used in IVF did not support
cryopreservation of biopsy embryos (slow freezing) but recent developments
of the vitrification technique have allowed highly successful cryopreservation
of biopsied embryos (Simopoulou et al.,2014, Chang et al., 2014). The use of
vitrification is being tested to determine if freezing all embryos in routine IVF
9cycles gives a higher success rate, as it allows for optimization of the
endometrium (Roque et al., 2015). These freeze-all cycles, open up the
opportunity to freeze all embryos post biopsy for PGD (Schoolcraft et al.,
2011, Taylor et al., 2014b). This relaxes the time constraints on the PGD
team to perform the diagnosis and allows batching of samples, both of which
make the test significantly cheaper and improves the quality of the test
results.
Accreditation of a PGD lab
Accreditation is a laborious process to establish and even harder to maintain
but it ensures good quality management which is essential in today’s
diagnostic laboratories. PGD diagnostic laboratories need to conform to ISO
15189 (international laboratory standard specific for medical laboratories -
Medical laboratories — Particular requirements for quality and
competence)(Harper et al, 2010). The ISO has two parts: management and
technical requirements. The ESHRE PGD Consortium have recommended
that PGD is only carried out in an accredited laboratory (Harton et al., 2011c)
and the HFEA in the UK have made this mandatory (HFEA, 2009). Similarly,
the Organisation for Economic Co-operation and Development (OECD)
“Guidelines for quality assurance in molecular genetic testing” (OECD, 2007)
state that “All laboratories reporting molecular genetic testing results for
clinical care purposes should be accredited or hold an equivalent recognition”.
PGD is slightly more complicated than some genetic testing as it requires a
dialogue between the IVF centre and the PGD laboratory and it can be
constrained by a short time period required for the test result.
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Under personal requirements, ISO 15189 states that the PGD laboratory shall
be directed “by a person or persons having executive responsibility and the
competence to assume responsibility for the services provided” (5.1.3).
The management requirements address quality management including the
quality policy and manual, document control, non-conformities and corrective
actions, continual improvement, auditing, management review, contracts,
referrals and resolution of complaints. Technical requirements include
personnel competence (both technical and medical), equipment,
accommodation and environment, and pre-analytical, analytical and post-
analytical processes. Emphasis is placed on the particular requirements of
patient care: notably sample identification and traceability, test validation, and
interpretation and reporting of results. Quality indicators must be developed to
monitor contributions to patient care and continual improvement.
The reports required
In PGD the protocol will need to be validated for the specific patient prior to
the start of the treatment cycle. In PGS each methodology (FISH, array CGH,
NGS) requires a separate validation prior to clinical application. This validation
should be recorded and authorised for clinical application within a work up
report. For validation appropriate control samples must be available.
Equipment used must be in working order supported by documented evidence
that it has been serviced and calibrated to the appropriate level for application
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of the PGD protocol. Quality control measures need to be specified to ensure
that the diagnostic results are within the acceptable limits of the reagent kits
and equipment that was used. Staff training records need to be readily
available to ensure that those performing the diagnostic tests are sufficiently
trained to do so. The final protocol should be validated with the appropriate
level of sensitivity for its intended use (polar body, single blastomere or 5-6
trophectoderm cells. Trend analysis of internal quality controls (diagnosis
rates, contamination rates, equipment performance, staff training and root
cause analysis of errors identified through audit) enables labs to identify good
practise and potential problems. Acting on this findings leads to prevention of
causes of misdiagnosis and improvement in the overall service.
For all cases there must be an authorised report for every PGD cycle, which
in the PGD setup is sent to the IVF unit. The report must have the name and
addresses of the PGD unit providing the results and IVF unit to which the
results are being reported. For document control purposes the report should
have a document name, number, the date of issue and the version number.
The individual page numbers and the total number of pages of the report
should be stated. There should be at least two identifiers for each partner
(e.g., name, date of birth, hospital number/ unique patient number) along with
the date of oocyte retrieval. For single gene disorders, the report should have
the disorder name, the gene involved and their respective MIM numbers. The
mutation being tested for should be written using the latest Human Genome
Variation Society (HGVS) mutation nomenclature along with the reference
sequence used to identify the mutation. For chromosomal disorders the
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chromosomal rearrangements should be described using the latest
International System for Human Cytogenetic Nomenclature (ISCN).
The date and time the samples are received in the PGD lab and the date and
time the results report are issued are important as they can help keep track of
the turn around times.
The results are best presented in a tabulated form and should include
interpretative comments to indicate which embryos are suitable for transfer.
An explanation of the results in the form of extra notes can be included which
describe the minimum criteria used to provide a result including the expected
error rates, which were determined during the work up of the protocol.
The report should be signed by the persons involved in carrying out the
diagnosis and authorised by an appropriately qualified senior member of staff.
External quality assessment
A requirement for accreditation is to participate in an external quality
assessment scheme, if available. EQA enables labs to compare their
diagnostic workflow with that from other laboratories. All parts of the process
can be assessed including the strategy for diagnosis, accuracy of results, the
information given in the reports and turnaround times. Wet EQA schemes give
labs the opportunity to test validated samples. Good practise and errors
identified by the scheme assessors are summarised and circulated back to all
participating labs in final scheme reports. EQA has the potential to identify
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both major and minor problems in staff training, and equipment maintenance
as well as ensure that the lab is performing tests that conform to current
published guidelines (Harton et al 2011 b and d). EQA is an excellent tool for
labs to objectively assess and improve the quality of their diagnostic service.
Participating labs are marked according to specific criteria resulting in a
satisfactory performance or poor performance score. Individual feedback is
given to each lab and labs can appeal poor performance scores. A panel of
PGD experts (Specialist advisory group) review the appeal and they may
uphold or revoke it. A lab with poor performance is required to complete a root
cause analysis of the reason(s) that led to poor performance. Unlike actual
clinical work, identification of poor performance in EQA does not only arise
due to misdiagnosis but is often due to a weak protocol that is vulnerable to
misdiagnosis, or poor or over - interpretation of the actual results obtained. A
review of the first three years of the molecular PGD scheme run by NEQAS
showed a marked improvement in the diagnostic reports submitted by all labs
as the scheme summary reports gave clear feedback as to what needed to be
included in them (Deans et al 2013). User meetings for the schemes provide a
forum for participants to meet and discuss any difficulties experienced in
performing the EQA. This process allows the EQA schemes to evolve and be
appropriate to changes in clinical practice of the participating labs such as the
introduction of new technologies.
PGD EQA for FISH based diagnosis
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The EQA for FISH based diagnosis was started in 2008 as a collaboration
between the Cytogenetics European Quality Assessment scheme (CEQAS)
and the ESHRE PGD Consortium. Since this time it has run annually as an
online system. This scheme is in two parts. In part I labs are sent two case
scenarios and asked to select suitable probes for a pre-implantation genetic
diagnosis work-up. Labs report the theoretical unbalanced and balanced
products of the chromosomal rearrangement. A prediction of viable or
frequently unbalanced products arising from the rearrangement enables labs
to determine the appropriateness of their probe selection by assessing the
limitations and their overall protocol and the risk of misdiagnosis due to probe
efficiency or number of rounds of hybridisation. In part II, labs receive
images of interphase nuclei from blastomeres with specified probe
combinations for the case senarios presented in part I. Labs report their
scoring of the FISH signals and interpretation of the results. In addition to the
two case scenarios labs can also attempt an educational case which is
marked but not scored.
PGD EQA for molecular based diagnosis
The molecular EQA was also started in 2008 as a collaboration between the
United Kingdom National External Quality Assessment Service (UKNEQAS)
and the ESHRE PGD Consortium. It has run annually as a wet method for
analysis of blastomeres and trophectoderm. The scheme has two parts. In
part 1 labs are sent a mock PGD referral with genetics reports of parental
mutations and appropriate relatives together with genomic DNA from these
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individuals. Labs design an appropriate molecular protocol for the germline
mutation(s). When the scheme first started almost all labs performed direct
multiplex PCR for diagnosis. More recently PGH and karyomapping are
approaches that are being applied. Labs are required to submit a workup
report with evidence, such as the haplotypes of the DNA samples to show that
the strategy taken conforms to current guidelines (Harton et al 2011b). The
strategy should ensure that allele dropout (heterozygous locus appearing to
be homozygous due to failure of amplification of one allele) or contamination
(maternal or external) can be detected. In Part 2 labs are sent single cells as
mock embryos from the couple described in the referral. Labs perform
diagnosis on these samples and then submit their lab reports together with
the haplotypes in a proforma. Labs could report on one or two cells from each
‘embryo sample’ depending upon their normal practise. In recent years labs
have been offered the option of having 4-5 cells together as a mock
trophectoderm biopsy sample to reflect changing practice of participating labs.
This scheme has been run for cystic fibrosis, fragile X, Huntington disease
and myotonic dystrophy type I.
EQA for the detection of aneuploidy or chromosomal imbalance by
molecular methods
In 2013 two pilots were offered for arrays as a collaboration between
UKNEQAS and CEQAS. Analysis for PB1 and PB2, blastomere and
trophectoderm have been offered as wet schemes. Amplified DNA from PBI
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and 2 samples and single cells or groups of cells were sent to labs for testing.
Labs reported chromosomal imbalances detected. Labs have performed
analysis by array CGH and more recently using NGS. These schemes are still
being run as pilots to ensure that appropriate samples are provided to labs
that give consistent results across a number of CGH or NGS platforms.
Follow up of untransferred embryos
One of the numerous difficulties in developing and validating PGD methods is
that potentially affected embryonic cells are only available when the couple go
through fertility treatment. Therefore it is essential to make use of the
untransferred embryos from a PGD cycle to confirm the diagnosis. An ESHRE
study of follow up on 940 untransferred embryos from PGD of monogenic
disorders found that 93.7% of were correctly diagnosed in the treatment cycle.
Diagnostic embryos accuracy was statistically significantly higher when two
cells were tested compared to one cell (P=0.001). Sensitivity was significantly
higher when multiplex protocols were used compared to singleplex protocols
(P=0.005) however multiplex PCR-based methods on one cell, were as
suitable as protocols involving two cells when the false negative rate was
considered (Dreesen et al 2013).
The shift to methodologies requiring whole genome amplified products has
the advantage of enabling the robust validation of new technologies. This is
because the same whole genome amplified product can be tested on different
platforms (Fiorentino et al 2014) and the impact on the results of altered
conditions of analysis (for example hybridization time on arrays) can be
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verified. The shift to trophectoderm biopsy at blastocyst stage has meant the
effect of mosaicism in the sample needs to be validated for each new platform
(Mamas et al 2012).
Internal controls
Biopsy, Tubing, labelling, or spreading of cells
Biopsy of cell(s) from an egg or an embryo is required for all PGD or PGS
applications. The tubing and spreading of the biopsied is the most crucial part
of the PGD/PGS process. If the cell(s) do not get in the PCR tube or the
spreading is not carried out optimally the analysis of the DNA cannot be
carried out leading to a no result or an inconclusive result. Oocytes and
embryos that are donated for research and training can be used as controls
by the embryologists to practice their tubing and spreading skills. For
additional controls, DNA from the embryologists/scientists performing the
biopsy and tubing should be included in the molecular tests being performed
to check for contamination. A log of this training should be kept and used to
determine the competency of the staff performing these tasks.
Clear FISH signals can be used as IQC for optimally spread blastomeres.
Consistency in successful amplification for samples from separate oocytes
and embryos, without maternal or other contamination for molecular analysis
is a good indicator of competency in tubing the biopsied cells.
FISH
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The main purpose of the FISH technique in PGD is to test for chromosomal
imbalances. Before a FISH protocol can be applied clinically it needs to be
optimised on lymphocytes using the appropriate probe combination that will
detect the chromosomal imbalance. Lymphocyte preparations from an
unaffected partner and partner with chromosome abnormality can be used as
controls to test probe strategy and to confirm reported chromosomal
abnormality. Efficiency of optimised FISH protocol determined in workup
control samples can be used as a calibrator of the test and the acceptable
values for the control samples during testing in the treatment cycle that were
determined at workup can be used as internal quality control. FISH is not an
efficient technique to perform for PGS as often not all chromosomes are
tested. When numerous chromosomes are tested, FISH is challenging. For
the majority of PGD cases the resolution of whole genome approaches such
as array CGH and NGS is sufficient for the detection for predicted imbalances
that can arise in embryos from patients with chromosomal rearrangements
without the need for patient specific protocols. Whole genome approaches
also allow for the option of checking aneuploidy in other chromosomes not
involved in the parental chromosomal rearrangement.
Whole Genome Amplification (WGA)
DNA from single cells or a clump of cells is whole genome amplified and used
in different platforms to detect chromosomal imbalances and single gene
disorders mainly by linkage analysis. The reagents required for whole genome
amplification are generally provided as a kit by manufacturers. Due to
artefacts or bias that may arise during WGA it is important to validate which
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type of WGA kit is suitable for each work flow with consideration of the
following parameters: the starting material ( PB, blastomere or
trophectoderm), the indication for testing (single gene disorder, chromosomal
rearrangement or PGS), the number of hours of WGA and the method of
subsequent analysis using the WGA product (PCR, array or NGS). A positive
control DNA sample of known concentration and a negative (no DNA) control
can be processed and analysed with the test samples. The quality of the
amplification can be assessed by visualising the size range and intensity of
the amplified product on agarose gel electrophoresis or the double stranded
DNA concentration of the product can be measured using an appropriate
method such as Qubit. Recording these parameters of the control sample
post WGA serves as an internal quality control by calibrating the efficiency of
amplification.
Array CGH
Different aCGH platforms are used in PGD for the purposes of chromosomal
imbalance detection. When available, samples with imbalance arising due to
the chromosomal abnormality (affected family member, CVS, etc) can be
used as controls. For internal quality control, QC measures as specified by
array manufacturer for labelling, hybridisation and scanning could be used.
The quality and accuracy of the profile and results from reference male and
female DNA samples should also be checked as an internal quality control.
Multiplex PCR
Multiplex PCR is used in PGD to detect single gene disorders including
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dominant de novo mutations known to be present in an affected parent. The
PCR protocols need to optimised on single cells for each family to include a
mutation detection method along with linked microsatellite markers. Single
cells from known normal, carrier and affected individuals (as appropriate and
available) from the family are used during the workup and during the
treatment cycle as controls. Efficiency and ADO rates of all loci included in
the final optimised multiplex PCR protocol developed in case work up are
calculated that can be used as calibrators for the PGD cycle. Similarly false
negative and false positive values for single cells of known mutational status
are calculated and referred to during the PGD diagnosis.
The linked STR markers included in the protocol provide IQC measures to
detect successful amplification, external and maternal contamination as well
as any crossover events that might occur.
PGH
PGH is utilised in PGD for the detection of single gene disorders where
linkage analysis can be carried out. DNA samples from family members who
have had genetic testing and have been found to carry the familial mutation
are used as controls.
Suitable informativity of markers linked to the mutation site is required to use
as calibrators. Sufficient amplification of linked informative markers to
distinguish haplotypes in phase with familial mutation or the normal allele,
together with contamination and crossover detection provide the IQC
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measures for PGH.
Karyomapping
Similarly to PGH, DNA samples from family members with known disease
status are used as controls and suitable informativity of the SNPs linked to the
mutation site is required. Sufficient amplification of linked informative markers
to distinguish haplotypes in phase with familial mutation or the normal allele,
together with contamination and crossover detection provide the IQC
measures for karyomapping.
NGS
NGS has been applied to PGS. Reagent kits and software are available for
different NGS platforms. For internal quality control, QC measures as
specified by the manufacturer of the NGS reagent kit and platform should be
followed. The quality and accuracy of the profile and results as well as the
depth of the sequence read, of a WGA product from a known euploid genomic
DNA sample can be used as a calibrator and an internal quality control.
Audit
Audits are an important part of quality control as they provide a means to
monitor the service at regular intervals.
There are three types of audits that can be carried out, namely vertical,
horizontal and examination audits. The aim of a vertical audit is to check the
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whole of the management system and processes, for example by following a
PGD case from the referral stage all the way through to the point when the
final PGD report is issued. This could include several parameters such as
referral system, document control, standard operating procedures, equipment
maintenance, health and safety issues and staff training.
A horizontal audit examines one component of a process on more than one
item. For example, a number of reagents could be checked for logging in
process, storage conditions and COSHH assessment.
An examination audit, where an examination process is witnessed while being
carried out, not only audits the accuracy of the SOP and its related
documents, but also provides an opportunity to assess the competency of the
person carrying out the procedure.
Any non-compliances from any of the audits should be recorded and have a
root cause analysis carried out. The outcomes of the audits can be used to
rectify the shortfalls of the management system and provide more staff
training if necessary and lead to quality improvements.
Key quality Indicators
Key quality indicators are required so the lab can monitor its overall
performance and capacity. Service improvements should be reflected in the
key quality indicators which can be used to formulate future plans for the lab,
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implement new technologies and change future practice. Key quality
indicators could include turn around times, diagnosis rates, contamination
rates, EQA performance and staff competency testing.
Conclusion
Quality control minimises the risk of misdiagnosis. All parts of the workup and
diagnostic procedure from the initial referral to the delivery of the final report
can be monitored with suitable controls and calibrators. Regular audit of these
parameters enables the lab to assess the performance of their service and
objectively measure improvements.
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